Determinants of C-reactive protein in chronic hemodialysis patients: Relevance of dialysis catheter utilization

Hemodialysis International

Volumn 12, Issue 2, 2008, Pages 236-243

  Hung, Adriana ^a,b   Pupim, Lara ^b   Yu, Chang ^b   Shintani, Ayumi ^b   Siew, Edward ^b   Ayus, Carlos ^c   Hakim, Raymond M ^b   Ikizler, Talat Alp ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c Fresenius Medical Care North America Inc ^*

Author keywords

Body mass index; C reactive protein; Catheter; Hemodialysis; Inflammation; Nutrition

Indexed keywords

ACETYLSALICYLIC ACID; ALBUMIN; ANGIOTENSIN RECEPTOR ANTAGONIST; C REACTIVE PROTEIN; CALCIUM; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PHOSPHORUS; PREALBUMIN; TRANSFERRIN;

ADULT; AFRICAN AMERICAN; AGE; AGED; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CATHETER REMOVAL; CAUCASIAN; COHORT ANALYSIS; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIALYSIS CATHETER; FEMALE; FOLLOW UP; GLOMERULONEPHRITIS; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HYPERTENSION; INFLAMMATION; KIDNEY FAILURE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PATIENT MONITORING; PREDICTION; RISK FACTOR; SEX DIFFERENCE; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; C-REACTIVE PROTEIN; CATHETERIZATION; COHORT STUDIES; FEMALE; HUMANS; INFLAMMATION MEDIATORS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; RENAL DIALYSIS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 41849104221     PISSN: 14927535     EISSN: 15424758     Source Type: Journal    
DOI: 10.1111/j.1542-4758.2008.00260.x     Document Type: Article

References (18)

1. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: Application to clinical and public health practice: A statement for healthcare professionals from the centers for disease control and prevention and the American Heart Association. Circulation. 2003; 107: 499-511.
2. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997; 336: 973-979.
3. Cook NR, Buring JE, Ridker PM. The effect of including C-reactive protein in cardiovascular risk prediction models for women. Ann Intern Med. 2006; 145: 21-29.
4. Pepys MB, Hirschfield GM. C-reactive protein: A critical update. J Clin Invest. 2003; 111: 1805-1812.
5. Stenvinkel P, Heimburger O, Paultre F, et al. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int. 1999; 55: 1899-1911.
6. Ammirati AL, Dalboni MA, Cendoroglo M, Draibe SA, Fernandes Canziani ME. Coronary artery calcification, systemic inflammation markers and mineral metabolism in a peritoneal dialysis population. Nephron Clin Pract. 2006; 104: C33-c40.
7. Ikizler TA, Wingard RL, Harvell J, Shyr Y, Hakim RM. Association of morbidity with markers of nutrition and inflammation in chronic hemodialysis patients: A prospective study. Kidney Int. 1999; 55: 1945-1951.
8. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int. 1999; 55: 648-658.
9. Yeun JY, Levine RA, Mantadilok V, Kaysen GA. C-reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis. 2000; 35: 469-476.
10. National Kidney Foundation. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis. 2005; 48: 16-153.
11. Teruel JL, Marcen R, Ocana J, et al. Clinical significance of C-reactive protein in patients on hemodialysis: A longitudinal study. Nephron Clin Pract. 2005; 100: C140-c145.
12. Nascimento MM, Pecoits-Filho R, Qureshi AR, et al. The prognostic impact of fluctuating levels of C-reactive protein in Brazilian haemodialysis patients: A prospective study. Nephrol Dial Transplant. 2004; 19: 2803-2809.
13. den Elzen WP, van Manen JG, Boeschoten EW, Krediet RT, Dekker FW. The effect of single and repeatedly high concentrations of C-reactive protein on cardiovascular and non-cardiovascular mortality in patients starting with dialysis. Nephrol Dial Transplant. 2006; 21: 1588-1595.
14. Movilli E, Brunori G, Camerini C, et al. The kind of vascular access influences the baseline inflammatory status and epoetin response in chronic hemodialysis patients. Blood Purif. 2006; 24: 387-393.
15. Movilli E, Feliciani A, Camerini C, et al. A high calcium-phosphate product is associated with high C-reactive protein concentrations in hemodialysis patients. Nephron Clin Pract. 2005; 101: C161-c167.
16. Kaysen GA, Dubin JA, Muller HG, Rosales LM, Levin NW. The acute-phase response varies with time and predicts serum albumin levels in hemodialysis patients. The HEMO study group. Kidney Int. 2000; 58: 346-352.
17. Tsirpanlis G, Bagos P, Ioannou D, et al. Exploring inflammation in hemodialysis patients: Persistent and superimposed inflammation. A longitudinal study. Kidney Blood Press Res. 2004; 27: 63-70.
18. Pastan S, Soucie JM, McClellan WM. Vascular access and increased risk of death among hemodialysis patients. Kidney Int. 2002; 62: 620-626.